Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Fineline Cube Apr 17, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Company Drug

Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia

Fineline Cube May 20, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...

Company Drug

FDA Gives Accelerated Nod to Amgen’s Imdelltra in Small Cell Lung Cancer

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Amgen (NASDAQ: AMGN)...

Company Drug

Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels

Fineline Cube May 20, 2024

Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...

Company Deals

Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition

Fineline Cube May 20, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Deals

Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review

Fineline Cube May 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Company Medical Device

Medtronic’s Advanced Mazor X Spinal Surgery Robot Receives Chinese Market Clearance

Fineline Cube May 20, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approval...

Company Deals

Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion

Fineline Cube May 20, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans...

Company Deals

Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services

Fineline Cube May 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Drug

Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer

Fineline Cube May 20, 2024

China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...

Company Drug

Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...

Company Drug

ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial

Fineline Cube May 20, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...

Company Digital

Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse

Fineline Cube May 20, 2024

Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with...

Company Drug

CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA

Fineline Cube May 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity

Fineline Cube May 20, 2024

Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...

Company Deals

Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models

Fineline Cube May 20, 2024

A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...

Company

HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor

Fineline Cube May 20, 2024

HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...

Company Drug

Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation

Fineline Cube May 20, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...

Company Drug

North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China

Fineline Cube May 17, 2024

North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...

Company Drug

HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024

Fineline Cube May 17, 2024

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...

Posts pagination

1 … 345 346 347 … 652

Recent updates

  • Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio
  • WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients
  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

Company Drug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.